Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-20-049860
Filing Date
2020-04-23
Accepted
2020-04-22 21:01:43
Documents
11
Period of Report
2020-06-09
Effectiveness Date
2020-04-23

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm2016499d1_def14a.htm DEF 14A 321335
2 GRAPHIC tm2016499d1_def14a-img01.jpg GRAPHIC 8346
3 GRAPHIC tm2016499d1_def14a-img02.jpg GRAPHIC 2101
4 GRAPHIC tm2016499d1_def14a-img03.jpg GRAPHIC 2657
5 GRAPHIC tm2016499d1_def14a-img04.jpg GRAPHIC 3428
6 GRAPHIC tm2016499d1_def14a-img05.jpg GRAPHIC 877
7 GRAPHIC tm2016499d1_def14a-img06.jpg GRAPHIC 924
8 GRAPHIC tm2016499d1_def14a-img07.jpg GRAPHIC 2119
9 GRAPHIC tm2016499d1_def14a-img08.jpg GRAPHIC 2601
10 GRAPHIC tm2016499d1_def14a-img09.jpg GRAPHIC 476822
11 GRAPHIC tm2016499d1_def14a-img10.jpg GRAPHIC 280843
  Complete submission text file 0001104659-20-049860.txt   1399507
Mailing Address 15 WEST 38TH STREET 10TH FLOOR NEW YORK NY 10018
Business Address 15 WEST 38TH STREET 10TH FLOOR NEW YORK NY 10018 (917) 438-4353
SELLAS Life Sciences Group, Inc. (Filer) CIK: 0001390478 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-33958 | Film No.: 20808998
SIC: 2834 Pharmaceutical Preparations